Intravenous use of rifampicin.
Nineteen seriously ill patients with suspected or verified tuberculosis were treated with a new formulation of rifampicin for intravenous use. The normal dosage was 300 mg twice a day. Local reactions at the injection site were noted in four patients but no serious adverse reactions were observed. The serum concentrations were similar to those after the same dose given orally.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D012293:Rifampin / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D013997:Time Factors; D014376:Tuberculosis / Q000188:drug therapy
D012293:Rifampin